5 results on '"Rodrigues, Nelson B."'
Search Results
2. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
- Author
-
Ling, Susan, Ceban, Felicia, Lui, Leanna M. W., Lee, Yena, Teopiz, Kayla M., Rodrigues, Nelson B., Lipsitz, Orly, Gill, Hartej, Subramaniapillai, Mehala, Mansur, Rodrigo B., Lin, Kangguang, Ho, Roger, Rosenblat, Joshua D., Castle, David, and McIntyre, Roger S.
- Subjects
KETAMINE ,PSILOCYBIN ,MENTAL depression ,SEROTONIN agonists ,DEFAULT mode network ,AMYGDALOID body ,NEURAL circuitry ,SEROTONIN receptors - Abstract
Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are identified as safe, well-tolerated rapid-acting antidepressants in adults with treatment-resistant depression, and also mitigate measures of suicidality. Psilocybin is a naturally occurring psychoactive alkaloid and non-selective agonist at many serotonin receptors, especially at serotonin 5-HT
2A receptors, and is found in the Psilocybe genus of mushrooms. Preliminary studies with psilocybin have shown therapeutic promise across diverse populations including major depressive disorder. The pharmacodynamic mechanisms mediating the antidepressant and psychedelic effects of psilocybin are currently unknown but are thought to involve the modulation of the serotonergic system, primarily through agonism at the 5-HT2A receptors and downstream changes in gene expression. It is also established that indirect effects on dopaminergic and glutamatergic systems are contributory, as well as effects at other lower affinity targets. Along with the direct effects on neurochemical systems, psilocybin alters neural circuitry and key brain regions previously implicated in depression, including the default mode network and amygdala. The aim of this review is to synthesize the current understanding of the receptor pharmacology and neuronal mechanisms underlying the psychedelic and putative antidepressant properties of psilocybin. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
3. Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.
- Author
-
Ceban, Felicia, Rosenblat, Joshua D., Kratiuk, Kevin, Lee, Yena, Rodrigues, Nelson B., Gill, Hartej, Subramaniapillai, Mehala, Nasri, Flora, Lui, Leanna M. W., Lipsitz, Orly, Kumar, Anil, Lee, Jung Goo, Chau, Edmond H., Cao, Bing, Lin, Kangguang, Ho, Roger C., Mansur, Rodrigo B., Swainson, Jennifer, and McIntyre, Roger S.
- Subjects
AFFECTIVE disorders ,KETAMINE ,MENTAL depression ,PATIENT selection ,BLOOD pressure - Abstract
The emerging roles of ketamine and esketamine as effective rapid-acting antidepressants hold promise for patients suffering from treatment-resistant depression and/or major depressive disorder with suicidality. Practitioner familiarity with common tolerability/safety concerns along with pragmatic prevention and management strategies are needed to reduce patient burden and improve the acceptability and accessibility of these treatments. The most common treatment-emergent adverse events associated with ketamine/esketamine are dissociation, anxiety, nausea, increased blood pressure, and headache. The majority of side effects are mild, transient, dose dependent, and attenuate with subsequent treatments. Patient selection, baseline physical and psychiatric assessments, and an appropriate setting are critical first steps in the prevention and mitigation of adverse events. Patient education and supportive interventions play central roles in the prevention and management of select adverse events. Severe and/or clinically significant adverse effects may necessitate the judicious use of adjunctive medications. Moreover, practitioners must remain vigilant to the potential for abuse liability and long-term adverse events, for which there are insufficient data. This article succinctly reviews common treatment-emergent adverse events of ketamine and esketamine within the context of mood disorders, and provides practical suggestions for prevention and management at point-of-care. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
- Author
-
McMullen, Eric P., Lee, Yena, Lipsitz, Orly, Lui, Leanna M. W., Vinberg, Maj, Ho, Roger, Rodrigues, Nelson B., Rosenblat, Joshua D., Cao, Bing, Gill, Hartej, Teopiz, Kayla M., Cha, Danielle S., and McIntyre, Roger S.
- Subjects
ANTIDEPRESSANTS ,SYSTEMATIC reviews ,KETAMINE ,MENTAL depression ,PSYCHOTHERAPY - Abstract
Introduction: Ketamine treatment is capable of significant and rapid symptom improvement in adults with treatment-resistant depression (TRD). A limitation of ketamine treatment in TRD is the relatively short duration of time to relapse (e.g., median 2-4 weeks). The objective of the systematic review herein is to identify strategies capable of prolonging the acute efficacy of ketamine in adults with TRD.Methods: PubMed/MEDLINE databases were searched from inception to December 2020 for clinical studies written in English using the following key terms: ketamine, prolong, and depression. A total of 454 articles were identified from the literature search which included all clinical studies regarding prolonging the antidepressant effects of ketamine. Twenty-two articles were included: ten randomized controlled trials (RCTs), eight prospective open-label trials, one retrospective chart review, and three case reports. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for data extraction. The primary outcome was prolonged effect, defined as statistically significant antidepressant effects following acute ketamine treatment.Results: A total of 454 articles were identified, and 22 articles were included. Different treatment modalites including pharmacological interventions, manualized-based psychotherapies, electroconvulsive therapy, transcranial magnetic stimulation, and intravenous monotherapy were examined to determine their impact on the prolongation of antidepressant effects following acute ketamine treatment. No treatment modality, other than repeat-dose IV ketamine, has demonstrated ability to significantly prolong the acute efficacy of IV ketamine in TRD.Conclusion: Hitherto, available open-label data and controlled trial data support repeat administration of IV ketamine as an effective strategy to prolong the efficacy of ketamine's antidepressant effects (although not the focus of the study herein, maintenance repeat-dose esketamine treatment is proven effective in esketamine responders). There is a need to identify multimodality strategies that are safe and capable of prolonging the efficacy of ketamine in adults with TRD. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment.
- Author
-
Ng, Jason, Lui, Leanna M. W., Rosenblat, Joshua D., Teopiz, Kayla M., Lipsitz, Orly, Cha, Danielle S., Xiong, Jiaqi, Nasri, Flora, Lee, Yena, Kratiuk, Kevin, Rodrigues, Nelson B., Gill, Hartej, Subramaniapillai, Mehala, Mansur, Rodrigo B., Ho, Roger, Cao, Bing, and McIntyre, Roger S.
- Subjects
AFFECTIVE disorders ,KETAMINE ,CYSTITIS ,GENETIC overexpression ,PROTEIN expression ,IMMUNOGLOBULIN E - Abstract
Intravenous (IV) ketamine has been shown to have rapid and robust antidepressant effects in adults with treatment-resistant depression (TRD). Urological toxicity has been observed in chronic ketamine abusers as evidenced by dysuria, urgency, and hematuria. The foregoing observation provides the basis for evaluating whether ketamine-induced urological toxicity (KIUT) is associated with sub-anesthetic doses of ketamine (0.5–1.0 mg/kg) in adults with mood disorders. The overarching objective of this article is to identify potential mechanisms of KIUT which appears to be dose and frequency dependent. Available research indicates that high-frequency ketamine is associated with disruption of the urothelial barrier as well as direct ketamine toxicity (i.e., decreased expression of junction proteins) in KIUT of the bladder. Chronic and high-frequency ketamine use is also associated with bladder inflammation mediated via neurogenic and IgE inflammation. Other non-mutually exclusive causes are nerve hyperplasia, hypersensitivity, cell apoptosis, microvascular damage, and overexpression of carcinogenic genes. Notwithstanding the evidence of KIUT in ketamine abusers, there is no evidence that ketamine and/or esketamine treatment in adults with mood disorders is associated with KIUT. However, all patients receiving ketamine/esketamine for mood disorder treatment should be queried about genitourinary symptoms during acute and, where applicable, maintenance dosing. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.